Cachexia: a therapeutic approach beyond cytokine antagonism (Q33960631)

30 July 2017

1 reference

title

Cachexia: a therapeutic approach beyond cytokine antagonism (English)

1 reference

30 July 2017

3

Anker SD

1 reference

30 July 2017

von Haehling S

1

1 reference

30 July 2017

Genth-Zotz S

series ordinal

2

1 reference

30 July 2017

Volk HD

series ordinal

4

1 reference

30 July 2017

publication date

1 September 2002

1 reference

International Journal of Cardiology

30 July 2017

published in

1 reference

30 July 2017

volume

85

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

173-183

1 reference

Metabolic and nutritional disorders in cardiac cachexia

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cardiac cachexia is a world-wide problem

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

The role of cytokines in cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Elevated soluble CD14 receptors and altered cytokines in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Loss of bone mineral in patients with cachexia due to chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Plasma cytokine parameters and mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Enhanced generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

1 reference

7 January 2021

Ubiquitin gene expression in skeletal muscle is increased during sepsis: involvement of TNF-alpha but not IL-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

The N-end rule pathway of protein degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

In vivo administration of interleukin-1 alpha induces muscle proteolysis in normal and adrenalectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Interleukin-6 induces skeletal muscle protein breakdown in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Molecular regulation of muscle cachexia: it may be more than the proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Proteasome inhibitors: valuable new tools for cell biologists

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Ubiquitin proteasome pathway: implications and advances in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

A proteolytic system that compensates for loss of proteasome function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cross-talk between pro-inflammatory transcription factors and glucocorticoids.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Multiple nuclear factors interact with the immunoglobulin enhancer sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

I kappa B: a specific inhibitor of the NF-kappa B transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

AP-1: one switch for many signals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cancer cachexia: a therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Mechanism of gene expression by the glucocorticoid receptor: role of protein-protein interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Biological effects of cyclosporin A: A new antilymphocytic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Mechanisms of action of cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

CYCLOSPORIN A INHIBITS THE IN VIVO PRODUCTION OF INTERLEUKIN-1β AND TUMOUR NECROSIS FACTOR α, BUT NOT INTERLEUKIN-6, BY A T-CELL-INDEPENDENT MECHANISM

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte-like cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Prevention of adjuvant-induced cachexia in rats by cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

FK506, an immunosuppressant targeting calcineurin function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

From beach to bedside: history of the development of sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Immunosuppressive and anti-inflammatory properties of interleukin 10.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Termination of acute-phase response: role of some cytokines and anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

The treatment of psoriasis with IL-10: rationale and review of the first clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Interleukin-10 and the interleukin-10 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

TGF-beta signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Proteasomal degradation of Smad1 induced by bone morphogenetic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Transforming growth factor-beta 1 inhibits synthesis of cytokines in endotoxin-stimulated human whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Clinical pharmacology of thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

New therapies for heart failure: is thalidomide the answer?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Characterization of a cancer cachectic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900245-0

7 January 2021

10.1016/S0167-5273(02)00245-0

Identifiers

DOI

1 reference

30 July 2017

1 reference